Parkin regulation predict large, unknown conformational changes during Parkin activation. However, current data on active RBR ligases reflect the absence of regulatory domains. Therefore, it remains unclear how individual RBR ligases are activated, and whether they share a common mechanism. We now report the crystal structure of a human Parkin-phosphoubiquitin complex, which shows that phosphoubiquitin binding induces movement in the 'in-between RING' (IBR) domain to reveal a cryptic ubiquitin-binding site. Mutation of this site negatively affects Parkin's activity. Furthermore, ubiquitin binding promotes cooperation between Parkin molecules, which suggests a role for interdomain association in the RBR ligase mechanism.
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, with symptoms including bradykinesia and tremor 1 . Although PD is primarily a sporadic disorder, mutations in several genes are associated with different Parkinsonism syndromes 2 ; examples include mutations in PARK2 (PRKN) and PARK6 (PINK1), which lead to autosomal recessive juvenile Parkinsonism 3, 4 . PARK2 and PARK6 encode Parkin E3 ubiquitin ligase and PTEN-induced kinase (PINK1), respectively, and maintain mitochondrial homeostasis [5] [6] [7] [8] . In addition to its role in mitochondrial protein control, Parkin also regulates protein degradation and induces aggresome formation by K63-linked ubiquitination [9] [10] [11] .
Parkin belongs to the RBR family of E3 ubiquitin ligases, characterized by a RING domain (RING1) followed by an IBR domain and a catalytic domain (RING2 or Rcat 12 ). RING1 is structurally similar to canonical RING-type E3 ligases, and shares the function of binding to E2 ubiquitin-conjugating enzymes. In contrast, RING2(Rcat) adopts a linear zinc-binding fold 13, 14 and possesses a catalytic cysteine capable of forming a thioester bond with activated ubiquitin 13, [15] [16] [17] [18] [19] . The linking IBR domain adopts the same fold as RING2(Rcat) 20 ; however, its functional role remains unclear. RBR ligases contain additional domains outside the RBR module. Parkin has an N-terminal ubiquitin-like (UBL) domain that shares 65% homology with ubiquitin, and a zinc-binding RING0 or unique Parkin domain 21 . Parkin adopts an autoinhibited conformation mediated by multiple domain-domain interactions [22] [23] [24] [25] [26] . This autoinhibition is released by PINK1-dependent phosphorylation of ubiquitin and the UBL domain of Parkin, thus leading to the activation of Parkin [27] [28] [29] [30] [31] [32] . The RBR ligase family also includes HOIP, which is a subunit of the linear ubiquitin chain assembly complex (LUBAC) 33 , and the human homolog of Ariadne, HHARI 34 . The catalytic activity of HOIP is also regulated through autoinhibition, mediated by its ubiquitin-associated (UBA) domain, which interacts with the other subunits of LUBAC, HOIL-1L and SHARPIN to activate HOIP 17, 33, 35, 36 . HHARI is also autoinhibited, and is mediated through its Ariadne domain 37 . HHARI activation requires interaction of the UBA domain of HHARI with NEDD8 (refs. 38, 39) . Thus our current understanding of Parkin and other RBR ligases suggests that there are distinct modes of regulation. In the case of Parkin, we and others have shown that the binding of phosphoubiquitin leads to Parkin activation via removal of the inhibitory effect of the UBL domain 23, 24, [40] [41] [42] [43] . However, all the structural insights into Parkin have been obtained in the context of the autoinhibited state [23] [24] [25] , or in the absence of the regulatory UBL domain 16, 25, 26, 43 . Insights into HHARI are also based on an inactive conformation 37 . Recent insights into the catalytic mechanism of the RBR family have come from structural and physical analyses of HOIP 14, 44 . The crystal structure of the catalytic RING2-like (RING2L) or Rcat domain of HOIP in complex with ubiquitin revealed how linear chains are assembled 14 , and a recent complex of the RBR module of HOIP in complex with a charged E2-ubiquitin conjugate revealed a series of allosteric ubiquitinbinding sites coupled to a swapped dimer of the RING2L(Rcat) domain between RBR molecules 44 . Furthermore, the RING2(Rcat) of HHARI has a ubiquitin-binding site that is important for E2-ubiquitin recruitment 45 , and the RING1 of HHARI supports an open conformation of the E2-ubiquitin conjugate. In contrast, a structure of the RING0-RBR (R0RBR) domains from Pediculus humanus corporis Parkin in complex with phosphoubiquitin does not show domain swapping between a r t i c l e s RBR modules; rather, it reveals a conformational change in the IBR domain that takes place after phosphoubiquitin binding 43 . Our current understanding is derived from snapshots of individual domains of large multidomain complexes. However, it remains unclear how RBR ligases function in the context of their regulatory domains, and whether they share a universal catalytic mechanism.
We report here the crystal structures of activated human Parkin (UBLR0RBR) and a phosphomimic Parkin (S65DUBLR0RBR) in complex with phosphoubiquitin at 2.7-Å and 2.6-Å resolution, respectively. All Parkin domains are present, and in contrast to the previous predictions of large conformational rearrangements upon activation, the Parkin structures reveal subtle, local changes that result in a series of cryptic ubiquitin-binding or ubiquitin-like-binding regions that are essential for Parkin function. We find an essential role of the IBR domain in ubiquitin recruitment and Parkin activity. Furthermore, comparative analyses with the HOIP and HHARI modules revealed common ubiquitin-binding or ubiquitin-like-binding sites. In particular, comparison with the RBR of HOIP suggests a potential unifying mechanism of cooperation between multiple RBR modules in the mechanism of ubiquitin ligase activity.
RESULTS

Structure of Parkin with pUb reveals activated state of Parkin
Previous studies by us and others suggest that the binding of phosphoubiquitin (pUb) to Parkin relieves the autoinhibition by the UBL domain. Consistent with this, the UBL domain binds more weakly to the R0RBR fragment of Parkin in trans after pUb binding 23, 24, [40] [41] [42] [43] 46 . To understand the allosteric regulation by pUb, we crystallized a complex of Parkin UBLR0RBR (∆84-143) with a pUb suicide probe (pUb bromopropylamine (pUb3BR)). To enable the formation of stable, well-diffracting crystals, we generated a covalent Parkin-pUb complex by ligating the pUb3BR probe to a cysteine residue on the surface of Parkin. The cysteine was generated via mutation of Gln347, as described previously 43 . The structure of activated Parkin was refined to 2.7 Å (Table 1) , with good geometry and refinement statistics. The crystal structure of the Parkin-pUb complex reveals the activated state of Parkin, containing all five domains of Parkin UBL, RING0, RING1-IBR-RING2(Rcat) and pUb ( Fig. 1a) . In the asymmetric unit, UBL, RING1-IBR-RING2(Rcat) is contributed from one molecule, whereas RING0 and pUb are from another molecule, with the biological unit formed via symmetry-related molecules ( Supplementary  Fig. 1a ). Comparison of the activated state of Parkin-pUb with the apo, inactive UBLR0RBR structure 23 shows that although some small rearrangements occur, the UBL-RING1 interface, which exists primarily between β3 and β5 of the UBL domain and helix H1 of the RING1 domain, remains largely intact in the presence of pUb ( Fig. 1b and Supplementary Fig. 1b ). The largest structural rearrangement after activation is the movement of the IBR domain. Helix H3 of the RING1 domain straightens, leading to global movement of the IBR domain (here we refer to this helix as H3-IBR), and creating a void between the UBL and IBR domains. This straightening of the H3-IBR helix is also observed in the insect Parkin R0RBR complex with pUb that lacks the UBL domain 43 . In the apo structure this UBL-IBR interface is formed primarily through interactions of His11 of the UBL domain with Lys369, Glu370 of the IBR domain, and surrounding residues, and these interactions are lost in the pUb-bound complex. Phosphorylation of the UBL domain by PINK1 has been shown to weaken the association of the UBL domain with R0RBR Parkin 23, 24, 42, 46, 47 . Therefore, we wondered whether the inclusion of a negative charge at Ser65 to mimic phosphorylation would lead to displacement of the UBL domain in the presence of pUb. To test this, we crystallized a covalent complex of S65D-UBLR0RBR Parkin with the pUb suicide probe. This structure, refined to 2.6-Å resolution, showed that the S65D-UBL domain remains associated with RING1 ( Supplementary Fig. 1c ). However, there are local conformational rearrangements between UBLR0RBR/S65SD-UBLR0RBR in complex with pUb and the apo structure of UBLR0RBR. In the apo structure of UBLR0RBR, residues 383-390-part of the tether that connects the IBR domain to the repressor element of Parkin (REP)-are disordered 23, 25 . In contrast, this tether (residues 387-390) is ordered and traceable in the wild-type Parkin-pUb complex, with Arg392 pointing toward the disordered side chain of Lys48 in the UBL domain. This Arg392-Lys48 creates an electrostatic repulsion, while Gln389 and Tyr391 cement the association of the UBL-RING1 interface, thus resulting in flexibility of the 62-65 loop in the UBL domain ( Supplementary Fig. 1a ). Upon the inclusion of a negative charge at position 65, Tyr391 relocates from the UBL-RING1 interface, which results in disorder of the IBR-REP tether and ordering of the 62-65 loop in the UBL domain ( Supplementary Fig. 1c ). We wondered whether mutation of these residues would enable the UBL domain to bind ∆UBL-Parkin in the presence of pUb. In the absence of pUb, the UBL domain associates with ∆UBL-Parkin (80-465) with a dissociation constant (K d ) in the low micromolar range [22] [23] [24] 43 ( Supplementary  Fig. 1d ). The presence of pUb blocks the interaction between UBL and ∆UBL-Parkin (Supplementary Fig. 1d ). Gln389Ala, Tyr391Ala and Arg392Ala mutation in ∆UBL-Parkin prevents UBL reassociation in the presence of pUb ( Supplementary Fig. 1d) . Given that the structures clearly show that the UBL-RING1 interface persists in the presence of pUb, we wondered whether the loss of association in solution could be due to a weakened UBL-IBR interface ( Fig. 1b) , rather than the UBL-RING1 a r t i c l e s interface. To test this, we expressed and purified human Parkin that lacked the IBR domain, and measured the interaction of the UBL domain with Parkin by isothermal titration calorimetry (ITC). The UBL domain did not associate with ∆UBL-∆IBR-Parkin (80-329, 383-465) ( Fig. 1c) . To investigate the role of the IBR domain, we assayed this mutant for E3 ligase activity. ∆UBL-Parkin was active in both the absence and the presence of pUb ( Fig. 1d) . In contrast, deletion of the IBR domain in ∆UBL-Parkin led to a complete loss of Parkin activity that could not be rescued by the addition of pUb. It is a possibility that removal of the IBR domain results in a constrained version of Parkin that lacks the flexibility needed for maintenance of its catalytic domains. To rule this possibility out, we purified ∆UBL-∆IBR-Parkin containing a ten-residue (Gly-Thr-Ser-Gly-Thr-Ser-Gly-Ser-Ala-Ser) (∆UBL-∆IBRxL10) linker to span the 28-Å distance required, and assayed for ubiquitination activity (Fig. 1d) .
These constructs that lack the IBR domain are folded and monodisperse, and migrate at the expected molecular weight, consistent with folded proteins. In contrast to wild-type and ∆UBL-Parkin, both ∆UBL-∆IBR-Parkin and ∆UBL-∆IBRxL10-Parkin lacked ubiquitination activity, even in the presence of pUb. Interestingly, phosphorylation led to repulsion between the surface of the UBL domain and the negatively charged 37 - a r t i c l e s surface of the IBR domain, thus supporting a weakened UBL-IBR interaction ( Supplementary Fig. 1e ). The observation that the UBL domain and pUb both interacted with IBR, on opposite sides, could explain the competitive mode of binding to Parkin that has been observed previously 23, 24 . Taken together, these results show that the activation of Parkin by pUb binding involves loosening of the UBL-IBR interface, caused by straightening of the H3-IBR helix. Furthermore, these experiments show that the association of the UBL domain with the rest of Parkin depends on the presence of the IBR domain in addition to the more extensive RING1 surface, and that Parkin activity requires an intact IBR domain.
Parkin activation exposes ubiquitin-binding surfaces essential for Parkin activity
The straightening of the H3-IBR helix caused by pUb binding results in the creation of a void between the UBL and IBR domains ( Supplementary Fig. 2a ). Intriguingly, analysis of the crystal packing of activated Parkin revealed that this void is occupied by the UBL domain of another molecule of Parkin (Supplementary Fig. 2b) . The UBL domain of Parkin shares 65% sequence similarity with ubiquitin. We therefore wondered whether the void created by the loosening of the UBL-IBR interaction, occupied in our crystal structures by the UBL domain of a second Parkin molecule, could accommodate ubiquitin.
To explore this idea, we modeled ubiquitin into the void (Fig. 2a) . This arrangement revealed surfaces on Parkin that could potentially interact with ubiquitin, which we refer to as ubiquitin-binding regions (UBRs) 1, 2 and 3 ( Fig. 2) . UBR1 is contributed by the UBL domain of Parkin, mediated by His11, Phe13, Arg33 and Gln34 (Fig. 2b) . Mutation of UBR1 residues on Parkin results in a minor reduction of ubiquitin chain formation, but no observable decrease in substrate ubiquitination (in this case Miro1) ( Fig. 2b) . UBR2 and UBR3 are formed on the straightened helix (H3) of RING1 and the IBR domain of Parkin, respectively. The potential ubiquitin-binding surfaces are mediated by Arg275, Gln317, Tyr318 and Glu321 on H3 of RING1, and by Arg334 and Pro335
Time (30 min Supplementary Fig. 2b) . The boundary of one UBLR0RBR-pUb complex (color-coded as in Fig. 1a ) is represented by a dashed line. (b) The UBL and ubiquitin-binding region 1 (UBR1). For clarity, UBL (green), modeled ubiquitin (gray), RING1 helices H1 and H3 (cyan), and the IBR domain (brown) are represented schematically (bottom), with the molecule-1 boundary of Parkin marked by a dashed line, and UBR1 marked by a black shaded region. We monitored the activity of UBR1 mutants by incorporating fluorescently labeled ubiquitin into ubiquitin chains, and observing Parkin autoubiquitination and Miro1 ubiquitination (right). A Coomassie-stained gel was used as a loading control. (c) Left, H3 of RING1 (cyan) and IBR (brown) make two important interfaces with ubiquitin (gray), shown as UBR2 and UBR3 (purple and red shaded regions, respectively, in the schematic at the bottom). Right, mutations in UBR2 and UBR3 of Parkin lead to a loss of Parkin E3 ligase activity in ubiquitin chain formation, Parkin autoubiquitination and Miro1 ubiquitination. Assay conditions were as described in b. (d) Chemical shift perturbation map obtained from NMR titration experiments in which 2 H, 14 N-labeled ubiquitin was titrated into a solution of a r t i c l e s of the β-hairpin on IBR (Fig. 2c) . Mutations in UBR2 (R275A, Y318A and E321A) and UBR3 (R334A) result in the loss of E3 ligase activity, in both ubiquitin chain formation and Miro1 ubiquitination (Fig. 2c) . Therefore, UBR2 and UBR3, but not UBR1, are important for Parkin activity. To further clarify which regions of activated Parkin interact with ubiquitin, we carried out NMR chemical-shift perturbation experiments on the R0RBR fragment of Parkin in complex with pUb ( Fig. 2d) . After the addition of unlabeled ubiquitin to the R0RBR-pUb complex, it was clear that the IBR domain was a major site of interaction. The largest chemical shift changes occurred for residues Gly329-Arg334 of the β-hairpin and the adjoining loop (Gly361-Ala363, Arg366) of the IBR domain. Changes were also observed in the straightened helix (H3) of RING (Arg314, Val324) near those observed in the crystal structure. However, several of these resonances were broadened by pUb binding and were therefore difficult to visualize in the NMR spectra. Nevertheless, this analysis shows a large ubiquitin interaction surface in activated Parkin that is consistent with that for the UBR2 and UBR3 sites predicted from the crystal packing analyses. These findings suggest a role for ubiquitin (or ubiquitin-like protein) binding at surfaces exposed upon pUb binding in the regulation of Parkin activity. Consistent with this, a recent study showed that modification of the IBR domain at Lys349 and Lys369 by the ubiquitin-like protein ISG15 positively regulates Parkin activity 48 . Interestingly, Lys349 is also a target of Parkin autoubiquitination activity 13 . Therefore, we wondered whether Parkin modification by ubiquitin can influence Parkin activity. To explore this possibility, we generated a covalently linked Parkin that carried a ubiquitin chain (UBLR0RBR347Cys~pUb-M1-(UBS65A) 3 ) to mimic polyubiquitinated Parkin (for clarity, we denote covalent complexes with a tilde (~), and noncovalent complexes with a dash). In comparison with that of UBLR0RBR347Cys~pUb or UBLR0RBR with pUb provided in trans, the activity of UBLR0RBR347Cys~pUb-M1-(UBS65A) 3 Fig. 2c ). Taken together, these data suggest an important role for the displacement of the UBL-IBR interface, thus revealing that modification of the IBR domain, phosphorylation of Ser65 in the UBL-IBR interface, and pUb binding to the IBR domain all contribute to the creation of a ubiquitin/UBL-binding region, and that ubiquitin binding stimulates Parkin activity.
was dramatically enhanced (Supplementary
The UBL-IBR ubiquitin-binding site recruits the donor ubiquitin
The arrangement of pUb of one molecule of Parkin and the UBL domain of a second molecule is reminiscent of the activator ubiquitin and donor ubiquitin recently described in the structure of the RBR domain of HOIP in complex with a charged E2 (ref. 44 ). (Fig. 3a) . Furthermore, interaction of the ubiquitin-conjugating enzyme UbcH7 with phosphorylated Parkin is enhanced 20-fold by the addition of pUb and the charging of E2 with ubiquitin 23, 49 . Thus, we wondered whether the ubiquitin-binding site created by the activation of Parkin by pUb could accommodate the charged E2-ubiquitin conjugate. To test this, we measured the interaction of UbcH7 or UbcH7-ubiquitin with phospho-Parkin (pParkin) or the UBR2 mutant pParkinE321A in the presence of pUb. ITC experiments showed a similar affinity of pParkin or pParkinE321A for UbcH7 (K d = 19 and 23.5 µM, respectively) in the presence of pUb, thus suggesting that mutation of the a r t i c l e s ubiquitin-binding region of Parkin does not interfere with E2 binding (Fig. 3b) . In contrast, although pParkin bound to UbcH7-ubiquitin with 30-fold higher affinity, this enhanced binding was diminished for pParkinE321A (~2.5-fold) (Fig. 3b) . In addition, size-exclusion chromatography of these complexes showed that mutation of Glu321 to alanine abolished the formation of the pParkin UbcH7-ubiquitin complex in the presence of pUb (Supplementary Fig. 3a) . We used ITC to rule out the possibility that mutation of Glu321 leads to loss of pUb binding (Supplementary Fig. 3b) . These data suggest that the ubiquitin carried by charged E2 binds at the UBRs in activated Parkin. Previous studies have shown that when the only source of ubiquitin is pUb, Parkin cannot catalyze ubiquitin chains 49, 50 . However, UbcH7 can be charged with pUb 50 . Furthermore, measurements of Parkin fragments interacting with either ubiquitin or pUb showed a similar isotherm profile, but with much tighter binding to pUb 23 . Both of these observations suggest that the pUb-binding pocket on the surface of Parkin is the dominant ubiquitin-binding site. Therefore, we wondered whether loading of E2 with pUb redirects the conjugate to the pUb-binding site on the Parkin, rather than to the donor-ubiquitin-binding site. To test this, we 'activated' Parkin either with pUb or with UbcH7 charged with pUb (Ubch7-pUb). Interestingly, UbcH7-pUb, but not UbcH7-ubiquitin, activated Parkin to a similar extent as pUb alone (Fig. 3c) . Taken together, these data suggest that the cryptic ubiquitin-binding site created between the UBL and IBR domains upon Parkin activation recruits the donor ubiquitin as carried by E2.
Cooperation between multiple Parkin molecules promotes ubiquitin transfer
Using the position of the UBL domain, the HOIP RBR/E2-ubiquitin structure, and the chemical shift perturbations on Parkin as guides, we modeled an activated Parkin-donor ubiquitin complex (Supplementary Fig. 4a ). In the model, with only one molecule of Parkin, it is difficult to envision how the E2 of the E2-Ub conjugate would reach the proposed E2-binding site at the base of RING1. In addition, it is difficult to determine how the ubiquitin would reach the catalytic cysteine in RING2(Rcat). Indeed, despite many efforts to understand how the catalytic cysteine in the RING2(Rcat) domain mechanistically directs Parkin activity, previous Parkin structures show that Cys431 of the RING2(Rcat) domain is ~35 Å away (using ). Furthermore, multiple groups have reported that Cys431 is occluded by RING0 (refs. 16, 25, 26) . In our crystal structure of the Parkin-pUb complex, one molecule of activated Parkin accommodates a UBL domain from a neighboring molecule, which we model as a donor ubiquitin. This modeled donor ubiquitin packs against the catalytic RING2(Rcat) domain of a neighboring Parkin molecule (Fig. 4a) . This quaternary arrangement of Parkin molecules can also accommodate an E2, with proposed interactions with the RING1 and REP of molecule 2, thus satisfying observed E2 interaction sites in HOIP and HHARI 44, 45 (Fig. 4a) . Therefore, we wondered whether the UBR2 donor-ubiquitin-binding site would affect the loading of ubiquitin onto the catalytic cysteine (Cys431). To test this, we designed an in vitro assay to evaluate the transfer of donor ubiquitin from E2 to the RBR catalytic residue. First, we generated a Parkin RING2(Rcat) mutant able to trap the catalytic Parkin-ubiquitin intermediate 13, 17 , referred to as R0RBR CH . This species has a serine in place of the catalytic cysteine (Cys431Ser) and a His433Ala mutation in order to trap an ester-bound ubiquitin and impede any subsequent discharge. This R0RBR CH Parkin species can be charged with ubiquitin and was sensitive to sodium hydroxide hydrolysis, which confirmed the RING2(Rcat)-ubiquitin ester link. The addition of pUb in this setup enhanced the RING2(Rcat) charging by around seven-fold, whereas a catalytic Cys431Ala mutant (R0RBR C431A) Parkin could not be charged with ubiquitin in either scenario (Fig. 4b) . We then generated a UBR2 patch mutant of Parkin in this background, R0RBR CH E321A. In contrast to R0RBR CH , this mutant is defective in ubiquitin charging even in the presence of pUb (26-fold less). Finally, a combined mutant of the pUb patch and the UBR2 patch (R0RBR CH H302A + E321A) demonstrated drastically reduced (60-fold less) ubiquitin charging of RING2(Rcat) (Fig. 4b) .
Recent studies have suggested a physiological role for self-association of Parkin molecules. For example, in 2013, researchers in two independent studies observed that catalytically compromised Parkin (Cys431 mutants) could not translocate to the mitochondria after PINK1 activation 15, 19 . However, coexpression of Cys431-mutant Parkin with either wild-type Parkin or Parkin with other mutations, including Arg275Trp, which would affect the UBR2 binding site, could rescue this translocation defect. These observations raise the possibility of cooperation between Parkin molecules. We demonstrated that mutation of the donor-ubiquitin-binding site UBR2 in Parkin results in the loss of Miro1 ubiquitination (Fig. 2c) . Thus, we wondered whether a constitutively pUb-bound form of Parkin could support the activity of otherwise inactive Parkin, in this case pParkinE321A. To test this, we took the crystallized species of Parkin UBLR0RBR covalently linked to pUb and titrated it into pParkinE321A (Fig. 4c) . We found that wild-type pParkin could ubiquitinate Miro1 (Fig. 4c) . The addition of UBLR0RBR or of UBLR0RBR covalently complexed with pUb did not further enhance this activity. In contrast, pParkinE321A was defective in Miro1 ubiquitination ( Fig. 4c and Supplementary  Fig. 4b) . However, the addition of equimolar amounts of active UBLR0RBR complexed with pUb rescued Miro1 ubiquitination to a greater extent than the UBLR0RBR~pUb complex alone did (Fig. 4c) .
These data suggest that the activity of inactive Parkin molecules can be stimulated by the presence of activated Parkin molecules. Taken together, these data demonstrate that Parkin molecules can function together to ligate ubiquitin.
DISCUSSION
Previous extensive characterization of Parkin has shown that Parkin exists in an autoinhibited state, mediated through multiple domaindomain interactions, including interaction at the UBL-RING1 interface, blocking of the proposed E2 binding site by REP, and the proposed occlusion of the catalytic cysteine, Cys431, by the RING0 domain 16, [22] [23] [24] [25] [26] . All these inhibitory mechanisms are relieved by the activation of Parkin by pUb 27, 28, 30 . pUb and the phosphorylated UBL domain are unable to simultaneously bind to R0RBR Parkin in solution in trans, which suggests allosteric regulation of Parkin by pUb binding 23, 24, 42, 46 . In addition, previous studies have led to predictions of large conformational changes in Parkin after activation. Interestingly, a computational analysis of Parkin suggests that phosphorylation of the UBL domain initiates a large change, mediated by the 65-amino-acid linker between the UBL domain and RING0 (residues 77-140) 47 . An important caveat of our current understanding of the mechanism of Parkin activity is that structures are either of fragments of Parkin (R0RBR) 16, 25, 26 or of all domains but without the UBL-RING0 linker 23, 24 . However, in a low-resolution structure of full-length rat Parkin, the linker is present in the protein but is completely disordered in the crystal, and cannot be modeled 25 . The UBL domain and R0RBR domains remain unchanged in the absence of the linker 23, 24 . Interestingly, although the linker length, but not the composition, is conserved down to Drosophila 23,24 , Parkin from nematodes does not have a long linker between the UBL and RING0 domains; therefore, the functional importance of this linker is still unclear.
Here we present a modified model for Parkin regulation based on the first structures of an RBR ligase in the activated state, complete with regulatory domains. Our structures reveal that in contrast to the large conformational changes that have been predicted for Parkin function, the activation of Parkin results in local rearrangements of Parkin domains to reveal ubiquitin-binding sites. These ubiquitin-binding sites recruit molecules of ubiquitin, or ubiquitin carried by an E2, a r t i c l e s to bridge Parkin molecules and allow the utilization of catalytic domains from neighboring molecules. In this model, the UBL-IBR interaction (Fig. 5a) is perturbed by UBL phosphorylation or pUb binding, thus displacing the IBR from the UBL domain (Fig. 5b,c) . This IBR displacement opens a ubiquitin-binding pocket on the helix (H3)-IBR surface. A (donor) ubiquitin on loaded E2 occupies this new pocket, and E2 occupies the proposed sites on RING1 and the RING2(Rcat) of the neighboring molecule of Parkin (Fig. 5d) .
The current data suggest that Parkin is unique in the RBR family in that it has a distinct structural arrangement of RING1-IBR-RING2(Rcat) domains, where RING2(Rcat) and RING1 are in juxtaposition. In contrast, in HOIP and HHARI, RING2(Rcat) and RING1 are separated by the IBR domain 37, 44 (Supplementary  Fig. 5a) . Although RBRs share a conserved catalytic RING1-IBR-RING2(Rcat) module, they are usually autoinhibited and activated via distinct mechanisms. Parkin autoinhibition is released by pUb binding or UBL phosphorylation [27] [28] [29] [30] [31] [32] , HOIP autoinhibition is released by UBA-mediated interactions with the LUBAC constituent HOIL-1L or SHARPIN 22, 29, 30, 33, 36, 38, 51 , and HHARI autoinhibition is released by NEDD8 binding at the UBA domain 38 . In the structure of full-length HHARI, the proposed NEDD8-binding pocket ( Supplementary  Fig. 5b ) corresponds to the pocket that is occupied by pUb or allosteric ubiquitin (Ub allo ) in active Parkin or HOIP, respectively. This suggests that NEDD8 binding to HHARI would have a similar effect as pUb or Ub allo binding has on Parkin and HOIP. Inactive HHARI and Parkin have a compact H3-IBR region (Supplementary Fig. 5c ). Active Parkin and HOIP structures enable pUb or Ub allo binding on one side of the H3-IBR region, which in the case of Parkin is occluded when inactive, and allows donor ubiquitin binding on the opposite side of the H3-IBR region (Supplementary Fig. 5d ). Therefore, we speculate that blocking the donor-ubiquitin-binding site on one side of the H3-IBR region, with relief upon pUb or Ub allo binding on the opposite side via opening of the H3-IBR region to allow donor ubiquitin binding, could be a common mechanism of regulation in RBR ligases.
The structure of HOIP-RBR in complex with loaded E2 also suggests that the RING1 and RING2(Rcat) of the same molecule cannot cross-talk, as they are not close enough to allow catalysis of thioester formation, mediated by the catalytic cysteines of E2 and RING2(Rcat) (Supplementary Fig. 5e ). In the active state of HOIP-RBR, the processive unit is formed by the RING2(Rcat) of molecule 1 and the RING1-IBR of a second molecule, where E2 interacts with the RING2(Rcat) of molecule 1 and RING1 of molecule 2, whereas the donor ubiquitin interacts with the RING2(Rcat) of molecule1 and the H3-IBR region of molecule 2 (Supplementary Fig. 5e ). In contrast, in Parkin the processive unit is formed by the RING1-RING2(Rcat) of molecule 1 and the IBR domain of molecule 2 (Fig. 5d) . This difference in the arrangement of domains between Parkin and HOIP, in the active state, is consistent with the differences in RING1-IBR-RING2(Rcat) structural organization in three dimensions (Supplementary Fig. 5a) . Interestingly, inter-and/or intramolecular pairing of RING1-RING2(Rcat)-IBR domains of RBRs with E2 and donor ubiquitin explains previous observations that Parkin and other RBRs favor the extended 'open' conformation of loaded E2 (refs. 44, 45) . Furthermore, previous studies have reported a role for Parkin oligomerization or self-association 15 , as well as ubiquitin-binding activity of Parkin 19, 22 . Our structures of active Parkin support the idea that PINK1 induces structural changes in Parkin that stimulate ubiquitin binding. In the context of the mitochondrial membrane environment, where Parkin functions in mitophagy 52 , high local concentrations of Parkin, recruited by PINK1-catalyzed phosphorylation of ubiquitin, could result in the feed-forward amplification of Parkin-mediated ubiquitination observed at the mitochondria 52, 53 . Furthermore, it has been reported that Parkin functions with the LUBAC, which comprises two RBR proteins in HOIP and HOIL-1L 54 . The structures reported here open up the possibility of cooperation between RBR modules, and therefore we speculate that there is a possibility that RBR ligases can function in concert.
It has long been predicted that within the RBR module, RING1 recruits E2 (ref. 55) , as recently formally demonstrated for HHARI and HOIP 44, 45 , and the RING2(Rcat) domain, which harbors the catalytic cysteine, is the catalytic intermediate domain 18 . However, a functional role for the IBR domain has been less clear. Our observation that covalent modification of the IBR domain enhances Parkin activity, and that deletion of or mutations in the IBR domain lead to a loss of Parkin activity, coupled with a recent report of increased Parkin activity after ISG15ylation on Lys349 and Lys363 of the IBR domain 48 , suggests a crucial role for the IBR domain in Parkin function. Our study suggests that the role of the IBR domain, together with H3 (the helix that connects RING1 and the IBR domain), is to mediate interactions with the inhibitory UBL domain in the inactive state and with the donor ubiquitin in the active state. Furthermore, the IBR and RING2(Rcat) domains of RBR ligases are structurally similar folds, each containing two β-hairpin turns. Comparison of Parkin and HOIP structures in the active state revealed that the IBR domain can interact with two ubiquitin molecules (pUb or Ub allo , and donor ubiquitin) spanning both β-hairpins (Supplementary Fig. 5f ). Similar to the IBR domain, the RING2(Rcat) of HOIP also interacts with two ubiquitin molecules (donor and acceptor ubiquitin) 14, 44 mediated by both β-hairpins (Supplementary Fig. 5g ). Interestingly, this observation furthers the idea that the ubiquitination process is facilitated by the inherent ability of E1, E2 and E3 proteins to interact with ubiquitin 56 . In our Parkin structures, only one ubiquitin-binding site is captured, predicted to be the donor-ubiquitin-binding site; the acceptor ubiquitin may occupy the opposite surface, similar to what is observed with HOIP ( Supplementary Fig. 5g ). However, we cannot rule out the possibility of subtle differences in the acceptor ubiquitin or in substrate recognition that result in different types of modifications by different RBR ligases.
Taken together, our data suggest a common mechanism of regulation in RBR ligases. First, autoinhibition takes place via the blocking of a donor-ubiquitin-binding pocket on H3-IBR. Second, autoinhibition is released by opening of the H3-IBR binding site by a UBL protein, such as pUb, NEDD8, ISG15 or ubiquitin itself. Third, donor ubiquitin binds on the H3-IBR, with bridging of RBR molecules to facilitate access to the catalytic cysteine. Given the importance of Parkin function in mitophagy and PD, an understanding of the multiple regulatory modes required for its function will provide a framework for the design of small molecules to modulate Parkin activity.
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